Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Response Imaging in Prostate Cancer.
Swiha M, Gafita A, Nguyen A, Emmett L. Swiha M, et al. PET Clin. 2024 Apr 25:S1556-8598(24)00024-5. doi: 10.1016/j.cpet.2024.03.009. Online ahead of print. PET Clin. 2024. PMID: 38670877 Review.
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes.
Swiha M, Papa N, Sabahi Z, Ayati N, John N, Pathmanandavel S, Crumbaker M, Li S, Agrawal S, Ayers M, Hickey A, Sharma S, Nguyen A, Emmett L. Swiha M, et al. J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014. Online ahead of print. J Nucl Med. 2024. PMID: 38637137
How to Report PSMA PET.
Swiha M, Ayati N, Oprea-Lager DE, Ceci F, Emmett L. Swiha M, et al. Semin Nucl Med. 2024 Jan;54(1):14-29. doi: 10.1053/j.semnuclmed.2023.07.007. Epub 2023 Aug 8. Semin Nucl Med. 2024. PMID: 37558507 Review.
Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS).
Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Swiha MM, et al. J Cancer Res Clin Oncol. 2022 Jan;148(1):225-236. doi: 10.1007/s00432-021-03672-w. Epub 2021 Jun 10. J Cancer Res Clin Oncol. 2022. PMID: 34110489 Free PMC article. Clinical Trial.
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.
Alghamdi MA, Amaro CP, Lee-Ying R, Sim HW, Samwi H, Chan KK, Knox JJ, Ko YJ, Swiha M, Batuyong E, Romagnino A, Cheung WY, Tam VC; Hepatocellular Carcinoma - Cancer Health Outcomes Research Database (HCC - CHORD) Consortium. Alghamdi MA, et al. Among authors: swiha m. Cancer Med. 2020 Jul;9(14):4918-4928. doi: 10.1002/cam4.3228. Epub 2020 Jun 11. Cancer Med. 2020. PMID: 32529797 Free PMC article.